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A systematic review was performed to evaluate the clinical effectiveness of docetaxel in combination with prednisolone (docetaxel is
licensed in the UK for use in combination with prednisone or prednisolone for the treatment of patients with metastatic hormone-
refractory prostate cancer. Prednisone is not used in the UK, but it is reasonable to use docetaxel plus prednisone data in this review
of docetaxel plus prednisolone) for the treatment of metastatic hormone-refractory prostate cancer. A scoping search identified a
trial of docetaxel plus prednisone vs mitoxantrone plus prednisone, but did not identify any trials comparing docetaxel plus
prednisolone/prednisone with any other treatments. Therefore, we considered additional indirect evidence that would enable a
comparison of docetaxel plus prednisolone/prednisone with other chemotherapy regimens and active supportive care. Systematic
searching (upto April 2005) identified seven randomised controlled trials. One large well-conducted trial assessed docetaxel plus
prednisone vs mitoxantrone plus prednisone; this showed statistically significant improvements with 3-weekly docetaxel in terms of
overall survival, quality of life, pain response and PSA decline. Two other chemotherapy regimens that included docetaxel with
estramustine also showed improved outcomes in comparison with mitoxantrone plus prednisone. Three trials that compared
mitoxantrone plus corticosteroids with corticosteroids alone were identified and their results for overall survival combined, which
showed very little difference between the two groups. The addition of clodronate to mitoxantrone plus prednisone showed no
significant differences in comparison with mitoxantrone plus prednisone alone. The evidence suggests that chemotherapy regimens
containing 3-weekly docetaxel are superior to mitoxantrone or corticosteroids alone.
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Prostate cancer is the most common cancer among men in the UK
(excluding nonmelanoma skin cancer), the lifetime risk for being
diagnosed with prostate cancer is one in 13 (Cancer Research UK,
2004). The majority of patients are diagnosed with early disease
and have a good prognosis. However, approximately 22% of cases
will be diagnosed with advanced or metastatic disease (National
Institute for Clinical Excellence, 2002), with an additional 25%
developing metastases throughout the course of the disease
(Muthuramalingam et al, 2004). The majority of prostate cancers
initially respond to hormone therapy, with a median response
duration in patients with metastatic disease of around 18 months
(Eisenberger et al, 1998). However, in most patients with
metastatic disease, the cancer will become resistant to hormonal
treatment and will progress to metastatic hormone-refractory
prostate cancer (mHRPC). Metastatic hormone-refractory prostate
cancer is defined as either biochemically or clinically progressive
metastatic disease despite castrate serum levels of testosterone
(Muthuramalingam et al, 2004). The prognosis for mHRPC is poor,
and survival in men with symptomatic metastases is not expected
to exceed between 9 and 12 months, once they have failed first-line
hormonal therapy (Petrylak, 2002).
Treatment for mHRPC is palliative. Options include second-line
hormonal therapy, chemotherapy and active supportive care,
and patients may receive a combination of palliative treatments.
Current advice issued by the National Institute for Health and
Clinical Excellence (NICE) states that chemotherapy should be
considered and trials of chemotherapy supported (National Institute
for Clinical Excellence, 2002). The taxane docetaxel (Taxotere
s,
Sanofi-Aventis, Guildford, UK) has recently been licensed for the
treatment of mHRPC in the UK, in combination with prednisolone.
(Docetaxel is licensed for use in combination with prednisone or
prednisolone for the treatment of patients with mHRPC. Prednisone
is not used in the UK, but it is reasonable to use docetaxel plus
prednisone data in this review of docetaxel plus prednisolone.)
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sThe Centre for Reviews and Dissemination (CRD) and the
Centre for Health Economics were commissioned to conduct a
systematic review on behalf of NICE of the clinical and cost-
effectiveness of docetaxel for the treatment of mHRPC. This paper
presents the systematic review of the effectiveness evidence. A full
technical report is available, which also presents the results of the
economic evaluation that was conducted alongside the systematic
review (Collins et al, 2006).
The objective of the systematic review was to evaluate the
clinical effectiveness of docetaxel in combination with predniso-
lone vs other chemotherapy regimens, active supportive care
(which may include radiotherapy, corticosteroids and analgesics)
or placebo for the treatment of mHRPC.
MATERIALS AND METHODS
A scoping search was conducted which identified a trial of
docetaxel plus prednisone vs mitoxantrone (Novantrone
s, Wyeth,
Maidenhead, UK) plus prednisone (Tannock et al, 2004). The
scoping search did not identify any trials comparing docetaxel plus
prednisolone/prednisone with any of the other relevant treatments.
However, trials comparing mitoxantrone with other chemothera-
pies and corticosteroids (used as active supportive care) were
identified. Therefore, in order to allow for a comparison between
docetaxel and other relevant treatments (albeit indirect), the
clinical effectiveness of mitoxantrone vs other relevant treatments
was also reviewed. Mitoxantrone is not licensed for the treatment
of mHRPC in the UK. However, it is licensed in combination with
corticosteroids for mHRPC in the USA and is widely given for
metastatic prostate cancer in the UK. In order to be inclusive, we
assessed mitoxantrone in combination with any form of corticos-
teroid.
Twenty-one electronic resources (MEDLINE, EMBASE, Co-
chrane Central Register of Controlled Trials (CENTRAL), the
Cochrane Database of Systematic Reviews (CDSR), National
Research Register (NRR), Health Technology Assessment Database
(HTA), NHS Economic Evaluation Database (NHS EED), Database
of Abstracts of Reviews of Effects (DARE), CINAHL, Health
Management Information Consortium (HMIC), ISI Science and
Technology Proceedings, Social Science Citation Index, Index to
Theses, SIGLE, Inside Conferences, BIOSIS Previews, Current
Controlled Trials, ClinicalTrials.gov, International Cancer Re-
search Portfolio (ICRP), National Cancer Institute Clinical Trials
PDQ, American Society of Clinical Oncology) were searched from
inception to April 2005. Index and free text terms were used to
search for prostate cancer and these terms were combined with
index and free text terms for docetaxel (including generic and
trade names). Separate searches were performed to combine the
prostate cancer terms with index and free text terms for
mitoxantrone. Where possible, subject index terms were used to
exclude animal studies. No language, date or study-type restric-
tions were applied. The reference lists of included and background
papers were also searched for additional relevant studies.
Published and unpublished randomised controlled trials
(RCTs) that compared docetaxel in combination with predniso-
lone/prednisone (as per its licensed indication) with any
chemotherapy regimen or active supportive care or placebo
in men with mHRPC were included. Randomised controlled trials
that assessed mitoxantrone in combination with a corticosteroid
(not licensed for mHRPC in the UK, but licensed in combination
with corticosteroids in the USA) compared with any chemotherapy
regimen or active supportive care or placebo in men with
mHRPC were also eligible for inclusion. Data on the following
outcomes were included: overall survival, progression-free survi-
val, response rate (including complete and partial response), PSA
decline, adverse effects of treatment, pain and health-related
quality of life.
Studies that were reported in abstract form only, where no
further information was available, and foreign language papers
were excluded. Where multiple publications of the same study
were identified, data were extracted and reported as a single study.
The quality of RCTs was assessed according to criteria based on
CRD Report No. 4 (Centre for Reviews and Dissemination, 2001).
Each stage of the review process was conducted by two reviewers,
with disagreements resolved by consensus or referral to a third
reviewer. A narrative synthesis is presented and, where appro-
priate, outcomes were synthesised using formal analytic ap-
proaches. Full details of the review methods, including the
search strategies, are described in the full technical report (Collins
et al, 2006).
RESULTS
A total of 1065 titles and abstracts were screened for inclusion in
the review and 267 records were ordered as full papers. Seven
RCTs were identified that met our inclusion criteria. The process
of study selection is shown in Figure 1.
Of the seven RCTs included, three used docetaxel compared
with mitoxantrone plus prednisone (Petrylak et al, 2004; Tannock
et al, 2004; Oudard et al, 2005), three used mitoxantrone plus a
corticosteroid compared with a corticosteroid (used as active
supportive care) (Tannock et al, 1996; Kantoff et al, 1999; Berry
et al, 2002) and one used mitoxantrone plus prednisone compared
with mitoxantrone plus prednisone plus clodronate (Ernst et al,
2003). There were no trials comparing docetaxel plus predniso-
lone/prednisone or mitoxantrone plus a corticosteroid with other
Titles and abstracts screened  
N=1065
Full copies ordered 
N=267 
Publications meeting
 inclusion criteria
N=29
Report unavailable 
N=5 
No such trial/no 
data/trial stopped 
N=5
Abstract only 
N=3
Ongoing trial 
N=4
Excluded
N=221
Background 
N=65
Overview
N=52 
Wrong patient group
N=15 
Wrong intervention  
N=12 
Not an RCT 
N=75 
Duplicate 
N=2 
Included studies 
N=7
(22 related publications)
Figure 1 Process of study selection.
Table 1 Treatment comparisons
Treatment comparisons
Trial D
a+P D
a+P+E D+E M+C M+C+Clo C
TAX 327 || (M+P)
Oudard et al (2005) || (M+P)
SWOG 9916 || (M+P)
Berry et al (2002) |(M+P) |(P)
CCI-NOV22 |(M+P) |(P)
CALGB 9182 |(M+H) |(H)
Ernst et al (2003) |(M+P) |
D¼docetaxel; P¼prednisone/prednisolone; E¼estramustine; M¼mitoxantrone;
C¼corticosteroid (either prednisone or hydrocortisone); Clo¼clodronate;
H¼hydrocortisone.
aEvaluated at two different dosages.
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sTable 2 Summary of included RCTs
Study details Results
TAX 327 (Sanofi-Aventis) Tannock et al (2004) Mortality: Intervention A vs control HR¼0.76 (95% CI: 0.62, 0.94).
Intervention B vs control HR¼0.91 (95% CI: 0.75, 1.11). Study design: Multicentre, stratified open-label RCT.
Progression-free survival: Not reported. Participants: 1006 men with metastatic prostate cancer, with disease
progression during hormonal therapy. Patients were required to have stable
levels of pain for at least 7 days before randomisation.
Response rate: Intervention A vs control RR¼1.65 (95% CI: 0.78, 3.48).
Intervention B vs control RR¼1.12 (95% CI: 0.49, 2.56).
Intervention A (n¼335): Docetaxel (75mgm
 2 on day 1 every 21
days)+prednisone or prednisolone (5mg orally twice daily from day 1) vs
Quality of life response: Intervention A vs control RR¼1.67 (95% CI: 1.14,
2.45). Intervention B vs control RR¼1.75 (95% CI: 1.20, 2.56).
Intervention B (n¼334): Docetaxel (30mgm
 2 on days 1, 8, 15, 22 and
29 in a 6-week cycle)+prednisone or prednisolone (as above) vs
Pain response: Intervention A vs control RR¼1.58 (95% CI: 1.1, 2.27).
Intervention B vs control RR¼1.40 (95% CI: 0.96, 2.03).
Control (n¼337): Mitoxantrone (12mgm
 2 on day 1 every 21
days)+prednisone or prednisolone (as above).
PSA decline: Intervention A vs control RR¼1.41 (95% CI: 1.14, 1.73).
Intervention B vs control RR¼1.5 (95% CI: 1.22, 1.84).
Grade 3/4 adverse events: Intervention A¼46%, intervention B¼43%,
control¼35%.
Oudard et al (2005)
Study design: Multicentre, stratified open-label RCT. Mortality: Intervention A vs control HR¼0.94 (95% CI: 0.29, 1.02).
Intervention B vs control HR¼0.86 (95% CI: 0.68, 1.08). Participants: 130 men with metastatic prostate cancer, with disease
progression despite androgen deprivation. Progression-free survival: Not reported.
Intervention A (n¼44): Docetaxel (70mgm
 2 on day 2 every 21
days)+estramustine (840mg in three divided doses on days 1–5 and 8–
12)+prednisone (10mg daily) vs
Response rate: Number of patients responding: Intervention A¼nine,
intervention B¼three, control¼one.
Intervention B (n¼44): Docetaxel (35mgm
 2 on days 2 and 9 every 21
days)+estramustine (as above)+prednisone (as above) vs
Quality of life response: Not reported.
Control (n¼42): Mitoxantrone (12mgm
 2 on day 1 every 21
days)+prednisone (as above).
Pain response: Intervention A vs control RR¼1.52 (95% CI: 0.74, 3.13).
Intervention B vs control RR¼1.11 (95% CI: 0.50, 2.45).
PSA decline: Intervention A vs control RR¼4.05 (95% CI: 1.99, 8.21).
Intervention B vs control RR¼3.71 (95% CI: 1.82, 7.58).
Grade 3/4 granulocytopaenia: Intervention A¼37%, intervention B¼0%,
control¼48%.
SWOG 9916 Petrylak et al (2004) Mortality: HR¼0.80 (95% CI: 0.67, 0.97).
Study design: Multicentre, stratified open-label RCT. Progression-free survival: HR¼1.30 (95% CI: 1.11, 1.52).
Participants: 770 men with metastatic prostate cancer, with disease
progression despite androgen-ablative therapy and cessation of anti-androgen
treatment.
Response rate: RR¼1.54 (95% CI: 0.74, 3.18).
Intervention (n¼386): Docetaxel (60–70mgm
 2 on day 2 every 21
days)+estramustine (three times daily on days 1–5) vs
Quality of life response: Not reported.
Control (n¼384): Mitoxantrone (12–14mgm
 2 on day 1 every 21
days)+prednisone (5mg twice daily).
Pain response: No significant difference (data not provided).
PSA decline: RR¼1.85 (95% CI: 1.49, 2.30).
Grade 3/4 adverse events: Intervention¼53%, control¼33%.
Berry et al (2002) Mortality: HR¼1.13 (95% CI: 0.75, 1.7).
Study design: Multicentre, open-label RCT. Progression-free survival: HR¼0.64 (95% CI: 0.48, 0.86).
Participants: 120 men with asymptomatic prostate cancer that had
progressed on at least one hormonal regimen. 86% intervention group and
79% control group had bone metastases, 18% in both groups had lymph
metastases.
Response rate: RR¼1.13 (95% CI: 0.20, 6.24).
Intervention (n¼56): Mitoxantrone (12mgm
 2 every 21
days)+prednisone (5mg orally twice daily) vs
Quality of life response: Not reported.
Control (n¼63): Prednisone (as above).
Pain response: Not reported.
PSA decline: RR¼2.03 (95% CI: 1.21, 3.40).
Grade 3/4 neutropaenia: Intervention¼48%, control¼10%.
Grade 3/4 leucopaenia: Intervention¼20%, control¼8%.
CCI-NOV22 (Lederle Laboratories) Tannock et al (1996) Mortality: HR¼0.91 (95% CI: 0.69, 1.19).
Study design: Multicentre, stratified open-label RCT. Time to progression: HR¼2.15 (95% CI: 1.46, 3.17).
Participants: 161 men with metastatic prostate cancer, with disease
progression despite standard hormonal therapy. Patients were required to
have symptoms of pain.
Response rate: RR¼2.33 (95% CI: 1.19, 4.57).
Intervention (n¼80): Mitoxantrone (12mgm
 2 every 21
days)+prednisone (5mg orally twice daily) vs
Quality of life response: Significant benefits for intervention group
compared with control group in terms of duration of improvement for several
items.
Control (n¼81): Prednisone (as above).
Pain response: Significant benefit for intervention group compared with
control group.
PSA decline: RR¼1.5 (95% CI: 0.81, 2.79).
Grade 3/4 adverse events: Intervention¼22, control¼15.
CALGB 9182 Kantoff et al (1999) Mortality: HR¼1.05 (95% CI: 0.74, 1.49).
Study design: Multicentre, stratified open-label RCT. Time to progression: HR¼1.50 (95% CI: 1.06, 2.13).
Participants: 242 men with metastatic prostate cancer. Antiandrogen
withdrawal and disease progression were required before trial entry.
Response rate: RR¼1.65 (95% CI: 0.56, 4.91).
Intervention (n¼119): Mitoxantrone (14mgm
 2 every 21
days)+hydrocortisone (30mg orally in the morning, 10mg orally in the
evening) vs
Quality of life response: Significant benefits for intervention group
compared with control group for some quality of life items.
Control (n¼123): Hydrocortisone (as above).
Pain response: Significant benefit for intervention group compared with
control group for pain severity.
PSA decline: RR¼1.74 (95% CI: 1.14, 2.66).
Grade 3/4 haematopoietic toxicities: White blood count:
Intervention¼59%, control¼1%. Granulocytes: Intervention¼63%,
control¼1%. Lymphocytes: Intervention¼70%, control¼15%.
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stypes of chemotherapy or active supportive care. A summary of the
pattern of comparisons for the included RCTs is presented in
Table 1 and detailed characteristics of the included RCTs are
presented in Table 2.
We identified one large well-conducted RCT that assessed the
intervention under consideration: docetaxel plus prednisone; this
was in comparison with mitoxantrone plus prednisone (TAX 327
trial) (Tannock et al, 2004). No other RCTs were found that
assessed the clinical effectiveness of docetaxel plus prednisone.
The RCT included 1006 men with mHRPC and stable levels of pain.
Patients were randomised to receive 3-weekly docetaxel plus
prednisone, weekly docetaxel plus prednisone or mitoxantrone
plus prednisone. The results of this RCT showed statistically
significant improvements with 3-weekly docetaxel plus prednisone
compared with mitoxantrone plus prednisone in terms of overall
survival (HR¼0.76 (95% CI: 0.62, 0.94)), quality of life response
(RR¼1.67 (95% CI: 1.14, 2.45)), pain response (RR¼1.58 (95%
CI: 1.1, 2.27)) and PSA decline (defined as a reduction in serum
PSA levels of 50% from baseline) (RR¼1.41 (95% CI: 1.14, 1.73)).
Response rate (defined as objective tumour response assessed
using World Health Organisation criteria) was higher for the 3-
weekly docetaxel plus prednisone group than the mitoxantrone
plus prednisone group, but this difference was not statistically
significant. The improved outcomes for docetaxel plus prednisone
were associated with more grade 3-4 adverse events. Progression-
free survival was not assessed in this RCT. There were also
statistically significant improvements with weekly docetaxel plus
prednisone compared with mitoxantrone plus prednisone in terms
of quality of life response (RR¼1.75 (95% CI: 1.20, 2.56)) and PSA
decline (RR¼1.5 (95% CI: 1.22, 1.84)), but not for any of the other
outcomes assessed.
We found three RCTs comparing mitoxantrone plus prednisone
with another chemotherapy regimen: one small RCT compared
mitoxantrone plus prednisone with 3-weekly docetaxel plus
prednisone plus estramustine and docetaxel twice every 3 weeks
plus prednisone plus estramustine in 130 men with mHRPC
(Oudard et al, 2005); one RCT compared mitoxantrone plus
prednisone with 3-weekly docetaxel plus estramustine in 770 men
with mHRPC (Petrylak et al, 2004); and one double-blind RCT
compared mitoxantrone plus prednisone plus placebo with
mitoxantrone plus prednisone plus clodronate in 227 men with
mHRPC and stable levels of analgesic use (Ernst et al, 2003).
Overall survival and progression-free survival were statistically
significantly improved with docetaxel plus estramustine compared
with mitoxantrone plus prednisone, response rate was statistically
significantly improved with docetaxel plus prednisone plus
estramustine compared with mitoxantrone plus prednisone and
PSA decline was statistically significantly improved for both
regimens containing docetaxel compared with mitoxantrone plus
prednisone. Docetaxel plus estramustine was associated with more
adverse events, compared with mitoxantrone plus prednisone. No
significant differences were found between mitoxantrone plus
prednisone plus clodronate and mitoxantrone plus prednisone
without clodronate.
In addition, we found three RCTs that compared mitoxantrone
plus a corticosteroid with a corticosteroid alone (used as active
supportive care). Two of these compared mitoxantrone plus
prednisone with prednisone (5mg twice daily) (Tannock et al,
1996; Berry et al, 2002), whereas one compared mitoxantrone plus
hydrocortisone with hydrocortisone (40mg given in two divided
doses daily) (Kantoff et al, 1999). One of the RCTs included 120
men with asymptomatic mHRPC (Berry et al, 2002); another
included 161 men with symptomatic mHRPC, with symptoms
including pain and disease progression (Tannock et al, 1996);
while the third study included all men with progressive mHRPC
(n¼242) (Kantoff et al, 1999). One RCT allowed patients to
crossover during the trial, this resulted in 50 out of 81 patients
randomised to prednisone to receive additional mitoxantrone
(Tannock et al, 1996); the other two RCTs did not allow crossovers.
The combined result of these three RCTs showed no significant
difference between mitoxantrone plus a corticosteroid compared
with a corticosteroid alone in terms of overall survival (HR¼0.99
(95% CI: 0.82, 1.20)). This result was exactly the same using fixed
effect and random effects approaches. Other outcomes could not
be pooled because they were measured differently in the three
RCTs. However, in the two studies that measured health-related
quality of life and pain response, the mitoxantrone groups had
statistically significant improvements compared with the cortico-
steroid groups for several of the quality of life and pain items
assessed (Tannock et al, 1996; Kantoff et al, 1999). High losses to
follow-up for these outcomes dictate that these results should be
interpreted cautiously.
In addition to the seven RCTs, four ongoing studies were also
identified. However, no further details of the studies were
obtainable from the trialists. The interventions that were assessed
in these trials were as follows: docetaxel plus prednisone plus
placebo vs docetaxel plus prednisone plus bevacizumab (Kelly,
2005), docetaxel plus prednisone vs GVAX
s prostate cancer
vaccine (Cell Genesys), docetaxel plus prednisolone vs docetaxel
plus prednisolone plus zoledronic acid vs docetaxel plus pre-
dnisolone plus strontium-89 vs docetaxel plus prednisolone plus
zoledronic acid plus strontium-89 (Trapeze trial) (James) and
mitoxantrone vs paclitaxel plus carboplatin (Cabrespine et al).
DISCUSSION
Key findings
The results of the only identified RCT to assess the intervention
under consideration (docetaxel plus prednisone) showed statisti-
cally significant improvements compared with mitoxantrone plus
prednisone in terms of overall survival, quality of life, pain
response and PSA decline (when given in 3-weekly doses). The
improved outcomes for docetaxel plus prednisone were associated
Table 2 (Continued)
Study details Results
Ernst et al (2003) Mortality: HR¼0.95 (95% CI: 0.71, 1.28).
Study design: Multicentre, stratified double-blind RCT. Progression-free survival: HR¼1.24 (95% CI: 0.93, 1.64).
Participants: 227 men with metastatic prostate cancer, with progressive
bone disease despite castrate levels of testosterone. Patients were required to
have stable levels of analgesic use for at least 7days before randomisation.
Response rate: RR¼1.14 (95% CI: 0.81, 1.59).
Intervention (n¼115): Mitoxantrone (12mgm
 2 every 21
days)+prednisone (5mg twice daily)+clodronate (1500mg over 3h every
21days) vs
Quality of life response: RR¼0.89 (95% CI: 0.64, 1.25).
Control (n¼112): Mitoxantrone (as above)+prednisone (as
above)+placebo (1500mg saline over 3h every 21 days).
Pain response: RR¼1.27 (95% CI: 0.83, 1.95)
PSA decline: RR¼1.04 (95% CI: 0.68, 1.59).
Grade 3/4 granulocytopenia: Intervention¼14, control¼14.
CI¼confidence interval; HR¼hazard ratio; RR¼relative risk; RCT¼randomised controlled trial.
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swith more grade 3–4 adverse events; however, this had no
detrimental effect on quality of life, which was significantly
improved. There were statistically significant improvements in
quality of life and PSA decline for patients receiving weekly
docetaxel, however, survival and pain response were not
statistically significantly improved. Two other chemotherapy
regimens that included docetaxel: docetaxel plus estramustine
and docetaxel plus prednisone plus estramustine, also showed
improved outcomes in comparison with mitoxantrone plus
prednisone in terms of overall survival, progression-free survival,
response rate and PSA decline. However, docetaxel in combination
with estramustine was associated with more adverse events. It
should be noted that these trials included patients with a
Karnofsky performance status score of at least 60%, or Eastern
Cooperative Oncology Group or Southwest Oncology Group
performance status score of 0–2; therefore, the results can only
be generalised to patients with a similar performance status.
Three trials that compared mitoxantrone plus a corticosteroid
with a corticosteroid alone were identified and their results for
overall survival were combined, which showed very little difference
between the two groups. The addition of clodronate to mito-
xantrone plus prednisone showed no significant differences in
comparison with mitoxantrone plus prednisone alone.
Limitations
The review was limited by the lack of trials assessing the
intervention under consideration: docetaxel plus prednisone. As
docetaxel plus prednisone has only been directly compared with
mitoxantrone plus prednisone, we considered additional evidence
that would enable a comparison of docetaxel plus prednisone with
other chemotherapy-based treatments and active supportive care.
The only form of active supportive care for which evidence was
available was corticosteroids. Therefore, no conclusions can be
drawn regarding the comparative effectiveness of docetaxel to
other types of active supportive care.
The small number of studies identified prevented the assessment
of publication bias using funnel plots or the Egger test (Egger et al,
1997). However, the risk is likely to be low, considering the
attempts to locate unpublished data, such as searching grey
literature and trials databases.
The three pooled RCTs that compared mitoxantrone plus a
corticosteroid with a corticosteroid alone differed in terms of the
patient population and study methodology, and in terms of
whether patients were allowed to crossover between treatment
groups. The difference in disease severity between patients
included in the RCTs may have affected the results; mitoxantrone
was more effective in the RCT of patients with symptoms of pain
and least effective in the RCT that only included asymptomatic
patients. However, the patients can be regarded as a relatively
homogeneous subset of patients with progressive mHRPC that
were healthy enough to receive chemotherapy. Including cross-
overs in intention-to-treat analyses can result in ‘dilution’ of the
true effects of a treatment, as patients are analysed as randomised.
However, in this case the study that allowed crossovers had a
stronger treatment effect in terms of overall survival in favour of
mitoxantrone plus prednisone than the two studies that did not
allow crossovers.
Implications for clinical practice
Docetaxel chemotherapy is the first agent to offer a survival
advantage, albeit modest, in patients with mHRPC. Of more
relevance is the demonstrable improvement in overall quality of
life, seen in almost twice the number of patients as those treated
with mitoxantrone and prednisone. This improvement takes into
account any side effects encountered owing to the chemotherapy.
Pain, which for many patients is the most debilitating symptom
and can be difficult to manage, was reduced in one-third of
patients treated with docetaxel. It is clear that docetaxel
chemotherapy is not without toxicity, and that the patients who
will gain from treatment are those with good performance status
(Karnofsky score of 60% or more). Careful patient selection by the
oncologist therefore remains paramount.
CONCLUSIONS
The limited evidence suggests that 3-weekly docetaxel plus
prednisone is superior to mitoxantrone plus prednisone in terms
of overall survival, quality of life, pain and PSA decline, and that
mitoxantrone plus a corticosteroid does not improve survival
compared with a corticosteroid alone. At the time of this
assessment, there were ongoing trials of docetaxel as the standard
arm in combination with other therapies.
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